The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade [Yahoo! Finance]
OPKO Health (NASDAQ:OPK) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock.
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat [Yahoo! Finance]
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting [Yahoo! Finance]